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audits of more advanced radiotherapy technologies such as 
IMRT is timely since they are becoming increasingly used for 
cancer treatment across the world.  
Materials and Methods: The CRP has developed new 
methodologies for four audit steps: (i) remote verification of 
TPS calculation of small beam output factors (ii) dosimetry 
audit of MLC positional performance for IMRT using 
radiochromic film, (iii) film audit of single clinical IMRT field 
dose delivery and (iv) ‘end-to-end’ dosimetry audit (imaging, 
planning, dose delivery) for multiple field IMRT techniques 
using TLDs and radiochromic films. New procedures and 
phantoms as well as instructions and data sheets for audited 
centres have been developed and are being tested through 
multinational pilot studies. The CRP has brought together 
research groups from 14 countries across the world. 
Results: The first CRP study developed and tested procedures 
for the audit of small beam output of high energy photon 
beams relevant for IMRT treatment planning. TPS calculated 
beam outputs were compared to the published reference 
data sets. The results show good agreement (within 1%) 
between the TPS output and the reference data for field 
sizes ≥ 4 × 4 cm2 but dose overestimation by TPSs by 2%-3% 
for field sizes ≤ 3 × 3 cm2. The second step evaluated MLC 
performance using picket fence tests and revealed that most 
audited MLCs perform as expected. The third step involved a 
comparison of gamma analysis techniques. This included a 
multicentre analysis of a single film irradiated with a 
complex field arrangement, which highlighted differences in 
gamma agreement attributable to the differences in film 
scanners and calculation algorithms employed in gamma 
analysis software. This test also included irradiation and 
analysis of a complex clinical field by each institution. Most 
results available to-date show good agreement between the 
TPS plans prepared by the participants and the dose 
distributions delivered to the films. The fourth step ‘end-to-
end’ IMRT audit is on-going. 
Conclusions: A four step methodology for remote dose audits 
for advanced radiotherapy dose delivery relevant to IMRT has 
been developed, and following the successful testing, is being 
made available. The CRP results thus far indicate challenges 
in TPS commissioning for small field sizes, and challenges for 
multicentre comparison of gamma analysis for complex dose 
distributions. 
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Purpose/Objective: The purpose of the present study is to do 
a retrospective analysis of the percentage-gamma-pass (%GP) 
values obtained from a large dataset of Tomotherapy pre-
treatment Quality Assurance (QA) to determine which are the 
pathologies and planning parameters more susceptible of 
producing poorer QA results. 
Materials and Methods: 384 Helical Tomotherapy (HT) pre-
patient QA were considered. For each plan, treated 
pathology and planning parameters ( field width (FW), pitch, 
modulation factor (MF), number of sinogram segments, 
calculation grid, gantry period, total treatment time, couch 
travel distance, fraction dose, simultaneous boost technique) 
have been reported. The 3D diode array ArcCHECK™ and 
3%/3mm , both with local and global normalization, gamma 
index metric has been used to perform comparison between 
measured and planned dose distributions. 
Results: We obtained an average %GP equal to (96.1±4.4), 
(92.5±7.5) and (96.9±4.7) for the %GP evaluated by using 
global and local with two dose difference threshold (DDT) 
equal to 3 and 5 cGy, respectively. The results of our analysis 
showed that %GP results depend, on one hand, on the GI 
calculation method, and, on the other hand, on the treated 
pathologies, which have different treatment planning 
parameters, dose prescriptions and extensions of irradiated 
volumes. In particular, a statistical dependence with 
irradiated length, maximum dose to diodes, dose per fraction 
and pitch was observed. Correlation Coefficient (CC) and p-
value (P) for the significance of the correlation between 
global and local %GP with DDT equal to 3 and 5 cGy and 
planning parameters are shown in the following table. 
 
  
Conclusions: Tomotherapy QA can generally achieve %GP 
higher than 90%. Attention should be paid when performing 
pre-treatment QA of plans with large pitch value, long 
irradiated volumes, high dose regions that falls on the 
ArcCheck’s diodes and high doses per fraction, because they 
are more susceptible of having a lower %GP. Nevertheless, 
%GP is independent on modulation factor.  
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Purpose/Objective: The 30-μm thick sensitive layer of EBT2 
film is coated onto a 175-μm thick polyester substrate while 
the overlaminate features a thickness of a mere 75 μm, 
consisting of 25-μm adhesive and 50-μm polyester. In 
literature, this asymmetric construction has been criticized 
as it introduces an extra dependence of the upside-down 
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orientation – in addition to the portrait-landscape 
dependence – when scanning the film. However, these 
dependences are manageable by a consistent film handling 
and scanning procedure, using the small slit marker provided 
by the manufacturer near a corner of each film. Instead, we 
explored whether combining a film and an upside down 
flipped one during exposure, hence creating a difference of 
100-μm polyester build-up, allows differentiating the dose 
within the steep superficial dose buildup, typical for photon 
beams. Our study was further motivated by the fact that the 
depth of the basal layer, containing the dividing cells in the 
human skin and being related to radiation-induced skin 
toxicity, varies from 40 to 100 μm (ICRP 59).  
Materials and Methods: First, a 6-MV 10x10-cm2 beam was 
investigated at 100-cm SSD and for 400 MU. Film pieces of 
1x3-cm2, marked for orientation, were put on top of a flat 
polystyrene phantom. Films were irradiated in pairs by 
flipping them upside down. All films were scanned (Epson 
Expression 1680) with the substrate layer down. Effects of 
field size, oblique incidence and increasing the photon 
energy to 18 MV were examined as well. Finally, a clinical 6-
MV 3-segment IMRT beam, belonging to a treatment plan for 
a mediastinal tumour, was investigated. 
Results: The 6-MV beam deposited doses of 82.6 cGy and 
99.9 cGy at water depths of 115 μm (substrate down) and 254 
μm (substrate up) respectively. The statistically significant 
dose difference of 17.3 cGy over 100 μm polyester reveals a 
dose gradient of 3.2 %/(100 μm water) relative to the dose at 
5-cm water depth. The gradient reached 3.7 % in a position 
offset to the beam axis and increased further for smaller 
field sizes. An oblique incidence of 45° resulted in a gradient 
of 4.0 %. The 18-MV beam resulted in a dose gradient of 1.5 
%/(100 μm water) relative to the dose at 10-cm water depth.  
The film-measured surface doses for the clinical IMRT beam 
(Fig. a and b) follows the same lines. The dose difference 
map (Fig. c) further demonstrates that the surface gradient 
increases with dose and with offset. 
 
 
 
Conclusions: The dose gradients measured at the surface are 
very steep in the 6-MV fields and their values are slightly but 
significantly higher than what we found in literature, 
presumably by virtue of the shallow reproducible 
measurement depths provided by EBT2 film.  
We developed a robust and versatile method to precisely 
assess the surface dose in pretreatment conditions. The 
extension to in-vivo dosimetry is straightforward and will 
guide us to manage skin toxicity in stereotactic body 
radiotherapy or setups with beam passage through the couch 
top and immobilization devices. 
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Purpose/Objective: The aim of this study is to assess the 
clinical feasibility of a measurement-based 2D EPID transit 
dosimetry model that can predict either: (1) in-vivo dose or 
(2) EPID transit dose, for actual treatment verification. 
Materials and Methods: The model was based on a quadratic 
equation that relates the reduction in intensity (given as the 
ratio of exit to entrance dose planes) with equivalent path 
length (EPL) of the attenuator. Two sets of quadratic 
equation coefficients were derived so that EPL can be 
calculated from either EPID or TPS entrance and exit dose 
planes. Consequently, either the in-vivo exit dose or the EPID 
transit dose can be predicted from the EPL. In addition to in-
vivo exit dose, doses at other planes (for example, isocentre) 
can also be predicted using information from patients' CT 
images and a 'CT number to EPL' calibration curve. The model 
was first tested on an anthropomorphic phantom using 65 
test fields (open, 3D conformal, wedge, and IMRT fields) with 
variable gantry angles. Finally, the model was used to verify 
the accuracy of patients' actual treatment. A total of 18 
fields were captured with EPID during patients' treatment and 
evaluated. Comparisons were done using 2D absolute global 
gamma analysis. 
Results: For the 65 fields tested on anthropomorphic 
phantom, the average gamma pass rates, using a 4%/4mm 
criterion, were 98.9%±1.20% (range: 95.7%-100%) and 
98.8%±1.35% (range: 95.2%-100%) for in-vivo comparisons at 
the exit and isocentre planes respectively. The average 
gamma pass rate was 98.0%±1.73% (range: 93.8%-100%) for 
direct comparisons at the EPID level. 
For the evaluation of patients' treatment fields, the average 
gamma pass rates, using a 5%/5mm criterion, were 
97.0%±1.90% (range: 92.4%-99.6%) and 98.6%±1.40% (range: 
96.1%-100%) for in-vivo comparisons at the exit and isocentre 
planes respectively. The average gamma pass rate was 
95.6%±2.30% (range: 90.7%-99.9%) for direct comparisons at 
the EPID level. 
Conclusions: A novel 2D EPID transit dosimetry model that 
can predict in-vivo doses at multiple planes as well as EPID 
transit dose has been shown to be clinically feasible. The 
model provides an additional safety net to ensure that 
patients' radiation treatments are accurately delivered as 
planned.  
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Purpose/Objective: Collaborative Ocular Melanoma Study 
(COMS) eye plaques contain silastic and Modulay materials 
